Your browser doesn't support javascript.
loading
Flibanserin for Treating Hypoactive Sexual Desire Disorder
Article in En | WPRIM | ID: wpr-10693
Responsible library: WPRO
ABSTRACT
There have been several products developed for male sexual dysfunction. However, developing agents for female sexual dysfunction is lagging behind for various reasons. Sildenafil citrate (Viagra) and Tadalafil (Cialis), which have been prescribed for male sexual function disorders, are known to act on vessels.[1] On the other hand, flibanserin is thought to act on brain. Flibanserin has been approved by U. S. Food and Drug Administration (FDA) for treatment of hypoactive sexual desire disorder (HSDD) of premenopausal women in 2015, and is expected to be released in South Korea soon. Authors wrote this article to acknowledge flibanserin to sexologists for females or physicians for menopausal medicine, so that this agent can be safely used for females who have HSDD.
Subject(s)
Key words
Full text: 1 Index: WPRIM Main subject: Sexual Behavior / United States Food and Drug Administration / Brain / Citric Acid / Sexual Dysfunctions, Psychological / Sildenafil Citrate / Tadalafil / Hand / Korea Limits: Female / Humans / Male Country/Region as subject: Asia Language: En Journal: Journal of Menopausal Medicine Year: 2016 Type: Article
Full text: 1 Index: WPRIM Main subject: Sexual Behavior / United States Food and Drug Administration / Brain / Citric Acid / Sexual Dysfunctions, Psychological / Sildenafil Citrate / Tadalafil / Hand / Korea Limits: Female / Humans / Male Country/Region as subject: Asia Language: En Journal: Journal of Menopausal Medicine Year: 2016 Type: Article